This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Pharmacology 2016

The British Pharmacological Society's flagship annual meeting attracts over 1,000 scientists each year, mostly from the UK but also many from across Europe and from overseas.

13–15 Dec 2016

Abstracts deadline: 09 Sep 2016

Registration deadline: 02 Dec 2016

Queen Elizabeth II Centre, London, UK - View map

  • Overview
  • Programme
  • Day 1
  • Day 2
  • Day 3
  • Photographs & Videos

Pharmacology is the flagship annual meeting of the British Pharmacological Society and attracts over 1,000 scientists each year, mostly  from the UK but also many from across Europe and from  overseas. The meeting includes a selection of topical symposia,  plenary lectures, free oral communications and poster sessions  which cover the whole spectrum of pharmacology.

We were delighted to host Pharmacology 2016 in association with guest Societies:

  • The American Society for Clinical Pharmacology and Therapeutics
  • The American Society for Pharmacology and Experimental Therapeutics
  • The Chinese Pharmacological Society

CPD (Continued Professional Development)

The Society was awarded 78 CPD credits from the Royal Society of Biology and 18 category 1 (external) CPD credits from the Royal College of Physicians.

Pharmacology 2016 supporters

Pharmacology-2016-Sponsor-overview-(1).jpg

Here's what attendees of Pharmacology 2015 had to say about the meeting:

 

We were delighted to confirm the following symposia for Pharmacology 2016:
Download the 'Programme'.

The following symposia was confirmed:

Cardiovascular and Respiratory Pharmacology

  • From bench to bedside: targeting the pathophysiological responses of ischemia-reperfusion injuries
  • Targeting cardiovascular GPCRs using biased agonism
  • Nanomedicine in pharmacology
 
Neuropharmacology
  • Uses and challenges for human pharmacology studies to understand CNS diseases
  • Fatty acid amides (aka lipoamines) beyond cannabinoids
  • Recent developments in research of melatonin and its potential therapeutics application
 
Integrative Systems Pharmacology
  • The long reach of the bowel: Translating microbiome science into therapeutics for systemic human diseases
  • Study, development and rationale use of immunopharmacological agents
  • Immuno-oncology: From bench to bedside
  • Translation to Therapeutics: Resolution of Inflammation
 
Molecular and Cellular Pharmacology
  • Non-traditional/orphan GPCRS as novel therapeutic targets
  • Biochemical strategies in drug discovery and targeting
  • Anti-tumor pharmacology and traditional Chinese medicine
 
Drug Discovery, Development and Evaluation and Toxicology
  • Organ-on-a-chip technology - the future of physiological profiling?
  • Clinical application of systems pharmacology models
  • Clinical pharmacology, pharmacokinetics and pharmacogenetics in pregnancy (C4P)


If you have any queries or need further information, please contact the Meetings Team (meetings@bps.ac.uk or +44 (0)20 7239 0176).

Satellite meeting for undergraduate, postgraduate and early career scientists
'Shaping the future of pharmacology'  took place on Monday 12 December. 

Download the 'Programme'.
Download the 'Symposium summary - Day 1'.
Download the 'Career Bootcamp programme'. 

Symposia summaries:

Track 1: From bench to bedside: targeting the pathophysiological responses of ischemia-reperfusion injuries

In addition to covering the diverse mechanisms important in I/R injury of different organs, the work presented highlighted a broad spectrum of scientific approaches to the problem of I/R injury. This was to help stimulate cross-pollination of ideas between different clinical and non-clinical disciplines.
The Society’s Equality and Diversity Statement was followed in preparation of this symposium.

The objective of this symposium was to bring together scientists and clinicians of all levels to discuss the diverse nature of IRI and potential therapeutic strategies to treat this disease area.

Track 2: Recent developments in research of melatonin and its potential therapeutics applications

A role for melatonin in modulation of sleep rhythms has been researched extensively.  However, recent developments in research of melatonin assign roles for this compound that impinge on a broader range of physiological systems.  This symposium focused on melatonin and its receptors and their influence on mood, behaviour, inflammation and metabolism, including their potential for pharmacotherapy in these fields.

The objective of the symposium was to draw attention to recent developments in research of melatonin and its receptors and to highlight its potential as a target for pharmacotherapy in some prominent and diverse disorders.

Track 3a: The long reach of the bowel: translating microbiome science into therapeutics for systemic human diseases

The overall objective was to present new findings regarding GPCR expression in a variety of cell types and tissues and the role of newly recognized non-traditional and orphan GPCRs in regulating organ function and as potential therapeutic targets.  

At the end of the program the audience had translational insights and a balanced view of the promise and challenges of microbiome hypothesis generation and testing, especially with respect to its metabolic role. They also learned about the latest pharmacological tools and potential therapeutic approaches for drug discovery using bacteria.

Track 3b: Resolution of inflammation: Translation to therapeutics

This symposium provided an overview of the field of resolution pharmacology and the potential for revolutionizing the treatment of inflammatory diseases, with examples of the broad range of endogenous mediators involved in this process, and the evolving clinical evidence suggesting that this approach will be successful.

Track 4: Non-traditional/orphan GPCRS as novel therapeutic targets

Professor Milligan provided an overview on the status of non-traditional/ orphan GPCRs and the opportunities that may exist to target such receptors with novel drugs (including biologics). The other speakers highlighted their findings that addressed several clinically important areas in need of new therapeutics (e.g., pulmonary hypertension, antibiotic resistance, Alzheimer’s Disease).

Track 5: Organ-on-a-chip technology - the future of physiological profiling?

(Sponsored by the Physiological Society and NC3Rs)

Tools which improve disease modelling and saftey pharmacology, as well as mitigate the use for animal testing are critical to the success of drug discovery and development.
Success in this area will rely on interdisciplinary relationships between pharmacologists, physiologists, physicists, drug developers and clinicians. In this symposium we aimed to bring together leading scientists and opinion leaders in these areas, in the hope of fostering collaborations and discussion to aid in improving the drug discovery and development process. As we represent the Young Pharmacologists Advisory Group of the British Pharmacological Society we also hoped this would provide an educational experience to young scientists and students, and provide networking opportunities.

Pharmacology-2016-Day-1-Symposia-speakers_page-1-(6).JPG
Pharmacology-2016-Day-1-Symposia-speakers_page-2-(9).JPG
Pharmacology-2016-Day-1-Symposia-speakers_page-3-(1).JPG
 

Download the 'Programme'.
Download the 'Symposium summary - Day 2'.
Download the 'Career Bootcamp programme'. 


Symposia summaries:

Track 1: Targeting cardiovascular GPCRs using biased agonism

This proposal represented the fourth in a programme of encouraging exchanges between BPS members and the British Society of Cardiovascular Research (BSCR). The previous embedded symposia, “New Drugs Targets for Cardiovascular Disease”, “Targeting cardiac metabolism”, and “Targeting cardiotoxicity”, were very successful, with excellent attendance, and highly positive feedback from both the audience and the speakers. BSCR were therefore pleased to submit this proposal for BPS 2016 with the objective of fostering further exchange and discussion between the societies on a topic of mutual interest.

Track 2: Uses and challenges for human pharmacology studies to understand CNS diseases

There is a general recognition that human pharmacology studies are becoming more important to aid in translation from animals to patients, particularly in areas like CNS where animal models have limited predictivity and low face validity. This symposium described some of these models and some of the issues surrounding their use for studying CNS disease. There is also a need for better pharmacological tools to use in human pharmacology studies and this is where the Medicines Chest initiative can help (Hayes & Nutt, 2015, Pharmaceutical Medicine, 29, 269-273. The ECNP 'Medicines Chest' Initiative: Rationale and Promise). Many selective compounds are languishing on the shelf after termination of development by Pharma companies and the Medicines Chest is an initiative to gain access to such compounds.

The objective of this symposium was to generate interest in the use of human pharmacology models in the CNS area and also in the use of selective pharmacological tools in such human studies.

Track 3: Immuno-oncology: From bench to bedside

It is increasingly recognised that immuno-oncology offers ‘game changing’ opportunities to treat a variety of cancers, some of which respond poorly to more traditional approaches. Innovative strategies to direct the cancer patients’ own immune system against the tumour are rapidly growing and major advances in therapy are promised that will transform cancer treatment. However it is also clear that some cancer patients do not respond to immuno-oncology agents. The objective of the symposium was to inform pharmacologists of the general field and recent advances in immuno-oncology with some specific strategies detailed along with up-to-date results.

Track 4: Biochemical strategies in drug discovery and targeting

The programme has been assembled to highlight numerous exciting biochemical technologies that facilitate drug discovery and targeting.

Symposium objectives:

  • Showcase a selection of biochemical strategies that are useful in drug discovery, repurposing and target validation.
  • Provide an opportunity for other researchers to showcase their research strengths in this field through associated posters.
  • Allow pharma representatives to introduce and increase uptake of their strategies for collaborating with academics.

Track 5: Clinical application of systems pharmacology models

Systems biology and pharmacology models are well-established tools in drug discovery where they enhance integrated understanding of the system under study. Their application in humans has been beginning to emerge over the last years, with their role in clinical drug development becoming an emerging science. The objective of this symposium was to exemplify how the pharmaceutical industry is using systems pharmacology models to assist with clinical development, to address how academia/industry partnerships can enhance this process, and how using these approaches with existing drugs can allow repurposing of the drugs and an improvement in their use.

Pharmacology-2016-Day-2-Symposia-speakers_page-1-(3).JPG
Pharmacology-2016-Day-2-Symposia-speakers_page-2-(2).JPG
Pharmacology-2016-Day-2-Symposia-speakers_page-3.JPG


 

Download the 'Programme'.
Download the 'Symposium summary - Day 3'.
Download the 'Career Bootcamp programme'. 

Symposia summaries:

Track 1: Nanomedicine in Pharmacology

Nanomedicine is a new and fast growing field that promises revolutionary advances in areas drug deliver pharmacokinetics, adjunct therapy and imaging. Importantly nanomedicine has utility for currently available small molecule drugs as well as biological therapies.   

Symposium objective:

  • To understand and learn the criteria used in choosing a specific nanoparticle to carry a specific drug
  • To understand different nanoparticles synthesis procedures and characterization methods
  • To identify how to load or link drugs to the chosen nanoparticles
  • To study the changes in the drug-nanoparticle conjugate

Track 2: Fatty acid amides (aka lipoamines) beyond cannabinoids

The objective of this symposium was to attract major researchers within this new field to highlight the expanding family of fatty acid amides. Specifically, the symposium was aimed to suggest potential novel therapeutic options, beyond the cannabinoid system, by reviewing evidence for lipoamine abundance, distribution, synthesis, metabolism/transformation, dietary manipulation and pharmacodynamics.

Track 3:  Study, development and rationale use of immunopharmacological agents

Immunoinflammatory responses play a key role in all the main chronic pathologies leading causes of death and morbidity including cancer, allergies, autoimmune and metabolic diseases. Much of the current research is now focused on understanding what drives these responses and how they are regulated. A better integration between all researchers and clinicians working in the fields of immunology, pharmacology and drug discovery would be strongly required for improving the study, development and rationale use of immune specific therapies. The aim of this symposium was to summarize our current understanding of inflammatory mechanisms and immune-therapies in allergic, inflammatory and autoimmune diseases. To achieve this goal we have invited a number of leading national and international clinical and basic scientists with an international track record and considered prominent researchers in their area.

Track 4: Anti-tumor pharmacology and traditional Chinese medicine

Further information will follow.

Track 5: Clinical pharmacology, pharmacokinetics and pharmacogenetics in pregnancy (C4P)

Symposium objective:

  • Highlight the current research in the field conducted in the UK and internationally. Invited speakers from the UK, US and Canada will talk about the unique physiology and pathology of pregnancy, pharmacokinetic studies in pregnancy, pharmacogenetics in pregnancy, pharmacokinetic model of pregnancy, clinical assessment of drug efficacy in pregnancy, multi-omics approaches to investigate preterm birth, etc.
  • Encourage multidisciplinary collaboration which may raise future funding
  • Raise awareness on drug safety and efficacy in pregnancy

Pharmacology-2016-Day-3-Symposia-speakers_page-1-(3).JPG
Pharmacology-2016-Day-3-Symposia-speakers_page-2-(2).JPG
Pharmacology-2016-Day-3-Symposia-speakers_page-3.JPG